Navigation Links
arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
Date:10/25/2012

BREDA, the Netherlands and GHENT, Belgium, October 25, 2012 /PRNewswire/ --

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the human anti-RANKL mAb denosumab, which was approved in 2010 by the U.S. Food and Drug Administration (FDA) under the trade name Prolia to treat osteoporosis in postmenopausal women and as Xgeva for the prevention of skeletal-related events in metastatic bone tumors. He was most recently responsible for leading more than 1,200 scientists in Amgen's discovery research unit across a portfolio of discovery and preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience.

Since Dr. Lacey's recent retirement, he remains active in the biopharmaceutical industry, advising a number of academic institutions, biotechnology companies and venture capital firms. Dr. Lacey holds an MD from the University of Colorado, USA, and carried out his postgraduate medical education training and research at Washington University, St. Louis, USA.

Tim Van Hauwermeiren, CEO of arGEN-X, said: "We are pleased to welcome David to our team, as his experience in antibody discovery and development will prove invaluable as we progress our innovative antibody programs into clinical development. With David on board, we are in an ideal position to further our company ambition as a first-in-class antibody discovery and development enterprise."

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging the power of its broadly applicable, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins.

The superior choice that arGEN-X brings to antibody discovery enables it to prioritise leads with best-in-class therapeutic properties, thereby increasing the probability of development success. Antibody leads generated from the SIMPLE Antibody™ platform have outstanding physicochemical properties and consistent manufacturability, enabling a seamless transition from discovery into development. arGEN-X has validated its technology on multiple diverse classes of target to date and has successfully delivered in its collaboration with Eli Lilly & Co. Early in 2012, arGEN-X announced a strategic alliance with Shire, focused on the discovery and development of monoclonal antibody therapeutics to treat rare diseases. In October 2012, arGEN-X granted a worldwide exclusive license to RuiYi (formerly Anaphore) to develop and commercialize ARGX-109, a novel anti-IL-6 SIMPLE Antibody™ discovered and developed by arGEN-X.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

In March 2012, arGEN-X obtained an exclusive global license to technology known as NHance™, to optimize the pharmacokinetic half-life of monoclonal antibodies and maximize their therapeutic utility.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.


'/>"/>
SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
2. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
3. Nephros Appoints John C. Houghton as President and Chief Executive Officer
4. Elsevier Appoints New President of Elsevier CPM Resource Center
5. GenWay Biotech Appoints New Vice President of Custom/OEM
6. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
10. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
11. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Tenn. , May 26, 2016 /PRNewswire/ ... of software and analytics, network solutions and ... today announced it entered into a strategic ... provider of outpatient software solutions and revenue ... centers, specialty hospitals and rehabilitation clinics to ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... Beleza Medspa has initiated a new program to ... the first time that Coolsculpting is being used for for more than just cosmetic ... they meet the prescribed body-fat standard, measured by the circumference-based tape method. The ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... in intellectual property (IP) to its specialty academic programs. , Answering to the ... college’s existing certificate programs in health law, and environmental and land use law. ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
Breaking Medicine News(10 mins):